Insights into IL‐29: Emerging role in inflammatory autoimmune diseases | Zendy

Wang JiaMin | Zendy; Huang AnFang | Zendy; Xu WangDong | Zendy; Su LinChong | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Insights into IL‐29: Emerging role in inflammatory autoimmune diseases

Author(s) -

Wang JiaMin,

Huang AnFang,

Xu WangDong,

Su LinChong

Publication year - 2019

Publication title -

journal of cellular and molecular medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.44

H-Index - 130

eISSN - 1582-4934

pISSN - 1582-1838

DOI - 10.1111/jcmm.14697

Subject(s) - rheumatoid arthritis , immunology , psoriasis , pathogenesis , medicine , signal transduction , multiple sclerosis , interleukin 17 , autoimmunity , inflammation , immune system , biology , genetics

Interleukin‐29 (IL‐29) is a newly discovered member of type III interferon. It mediates signal transduction via binding to its receptor complex and activates downstream signalling pathways, and therefore induces the generation of inflammatory components. Recent studies reported that expression of IL‐29 is dysregulated in inflammatory autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, osteoarthritis, Sjögren's syndrome, psoriasis and systemic sclerosis. Furthermore, functional analysis revealed that IL‐29 may involve in the pathogenesis of the inflammatory autoimmune disorders. In this review, we will systematically review the current knowledge about IL‐29. The information collected revealed the regulatory role of IL‐29 and may give important implications for its potential in clinical treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research